Ranibizumab Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 10 mg/mL
Reference Brands: Lucentis (USA/EU)
Category:
Opthalmology
Ranibizumab is available in Injection
and strengths such as 10 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ranibizumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ranibizumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ranibizumab is a vascular endothelial growth factor (VEGF-A) inhibitor used to manage and treat a variety of retinal disorders caused by abnormal blood vessel growth. Its approved indications include neovascular age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), myopic choroidal neovascularization, and diabetic retinopathy.
Ranibizumab works by binding to VEGF-A, preventing it from stimulating the formation of new blood vessels in the retina. This action reduces fluid leakage, limits retinal damage, and helps slow the progression of vision loss. Administered as a sterile intravitreal injection, ranibizumab requires careful monitoring to ensure safety and efficacy, including assessment of ocular and systemic adverse events.
Its well-established mechanism, targeted therapeutic effect, and wide range of ocular indications make ranibizumab a cornerstone in the management of retinal vascular diseases. Proper understanding of its pharmacodynamics, pharmacokinetics, dosing, adverse effect profile, and contraindications enables healthcare professionals to optimize patient outcomes in ophthalmology.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing